Acute Respiratory Distress Syndrome (ARDS) Pipeline Research Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Acute Respiratory Distress Syndrome (ARDS) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Acute respiratory distress syndrome (ARDS) pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute respiratory distress syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve Acute respiratory distress syndrome (ARDS).

Acute respiratory distress syndrome (ARDS) Emerging Drugs Chapters

This segment of the Acute respiratory distress syndrome (ARDS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute respiratory distress syndrome (ARDS) Emerging Drugs

BIO-11006: BioMarck Pharmaceuticals

BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. It is a ten-amino acid peptide that inhibits the phosphorylation of the MARCKS protein (myristoylated alanine rich protein kinase C substrate), which is a substrate for protein kinase C. BIO-11006 is in Phase II clinical studies for the treatment of Adult respiratory distress syndrome, chronic obstructive pulmonary disease, and Non-small cell lung cancer.

MultiStem: Athersys

MultiStem is an "off-the-shelf" stem cell product candidate, manufactured from Multipotent Adult Progenitor Cells. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. The drug is in Phase III clinical studies for the treatment of ischemic stroke and acute respiratory distress syndrome (ARDS).

The therapy has the equivalent of Fast Track status in Japan. In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the acute respiratory distress syndrome (ARDS) program.

Acute respiratory distress syndrome (ARDS): Therapeutic Assessment

This segment of the report provides insights about the different Acute respiratory distress syndrome (ARDS) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute respiratory distress syndrome (ARDS)

There are approx. 60+ key companies which are developing the therapies for Acute respiratory distress syndrome (ARDS). The companies which have their Acute respiratory distress syndrome (ARDS) drug candidates in the most advanced stage, i.e. Phase III include, Athersys.

Phases

This report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acute respiratory distress syndrome (ARDS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute respiratory distress syndrome (ARDS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute respiratory distress syndrome (ARDS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute respiratory distress syndrome (ARDS) drugs.

Acute respiratory distress syndrome (ARDS) Report Insights

• Acute respiratory distress syndrome (ARDS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute respiratory distress syndrome (ARDS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

• How many companies are developing Acute respiratory distress syndrome (ARDS) drugs?
• How many Acute respiratory distress syndrome (ARDS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute respiratory distress syndrome (ARDS)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute respiratory distress syndrome (ARDS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute respiratory distress syndrome (ARDS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Faron Pharmaceuticals
• BioMarck Pharmaceuticals
• Athersys
• Apeiron Biologics
• Cynata Therapeutics
• Orbsen Therapeutics
• GEn1E Lifesciences
• Exvastat
• Longeveron
• CohBar
• ZyVersa Therapeutics
• Abbreos
• Aviceda Therapeutics
• ImStem Biotechnology
• Bayer
• AVM Biotechnology
• Cartesian Therapeutics
• Sage Therapeutics
• Roivant Sciences
• ZyVersa Therapeutics
• Aerpio Pharmaceuticals
• Apeiron Biologics

Key Products

• Traumakine
• BIO-11006
• HLCM 051
• APN-01
• CYP 001
• Orbcel-C
• GEn1E-1124
• Imatinib
• Lomecel-B
• CB5064 analogs
• IC 100
• ABB-201
• IMS 001
• AVD-1010
• BAY 1097761
• AVM0703
• Descartes-30
• Brexanolone
• Gimsilumab
• IC 100
• Razuprotafib
• APN401

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5bsua6

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900